Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research

FHS
April 22, 2024
12:54 pm

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes.

New zebrafish xenograft platform could help screen for glioblastoma treatments

Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, according to a new study

October 5, 2023

Side Benefit of Botulinum Toxin A? Reduced IOP in Hemifacial Spasm

Injection with botulinum toxin A (BTX-A) for hemifacial spasm (HFS) may have an additional benefit: decreasing unilateral eyelid spasms and intraocular pressure (IOP), according to

October 30, 2023

Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech’s Phase 2b Study | Psychedelic Invest

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on

December 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.